Eric Groen
About Eric Groen
Eric Groen is General Counsel of Rani Therapeutics, serving since July 2021; he is 54 years old as of March 31, 2025, and holds a B.A. in Political Science from UC Santa Barbara and a J.D. from Harvard Law School . He previously spent nearly 20 years at Amgen in senior legal roles, most recently as regional general counsel for Canada, Latin America, Middle East and Africa, and earlier served as corporate counsel at HealthNet (1999–2001) and as an associate at TroyGould . The company highlights adherence to an insider trading policy (including prohibitions on hedging/pledging) and a Dodd-Frank-compliant clawback policy applicable to executive officers, which frame compensation alignment and risk management for executives like the General Counsel .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Rani Therapeutics | General Counsel | Since July 2021 | Senior legal leadership supporting BD, clinical, operations/manufacturing |
| Amgen Inc. | Various senior legal roles; Regional General Counsel (Canada, LatAm, MEA) | Nearly 20 years (specific dates not disclosed) | Led legal teams across BD, operations, manufacturing, clinical trials; regional commercial legal leadership |
| HealthNet | Corporate Counsel | 1999–2001 | Corporate legal counsel at a public managed care holding company |
| TroyGould | Associate | Not disclosed | Foundational legal practice experience |
External Roles
No public company directorships or external board roles disclosed for Eric Groen in the company’s 2024 or 2025 proxy statements .
Fixed Compensation
- Not a Named Executive Officer in 2024 or 2025; therefore, base salary, target bonus %, and actual bonus paid for Eric Groen are not disclosed in the Summary Compensation Tables (which cover only CEO, CSO, and CFO) .
Performance Compensation
- Company-wide bonus framework exists, with corporate goals set annually by the Board/Compensation Committee; however, specific targets, weightings, or payouts for Eric Groen are not disclosed. The Board exercised discretion to award no cash bonuses for 2023 and 2024 to Named Executive Officers due to the company’s financial position; applicability to General Counsel is not disclosed .
Equity Ownership & Alignment
- Beneficial ownership tables list certain directors and Named Executive Officers; Eric Groen is not individually listed, and his total beneficial ownership (including vested/unvested breakdown and options) is not disclosed in the 2024 or 2025 proxy statements .
- Hedging, short sales, margin purchases, derivative trading, and pledging of company stock are prohibited for all employees, directors, and consultants (alignment-positive; reduces hedging/pledging red flags) .
- The company has implemented a Dodd-Frank-compliant clawback policy; executive officers may be required to reimburse incentive-based compensation following certain restatements (alignment with accountability) .
- Indemnification is provided to directors and executive officers under bylaws and individual indemnity agreements (standard governance practice) .
Employment Terms
- Start date and tenure: General Counsel since July 2021 (at-will employment status not specifically disclosed for General Counsel) .
- Severance/Change-of-Control: The company’s Severance and Change in Control Plan disclosures explicitly cover Named Executive Officers (CEO, CSO, CFO) with cash severance, benefits, and equity acceleration; participation terms for General Counsel are not disclosed .
- Clawbacks: Dodd-Frank-compliant clawback policy implemented; executive officers subject to reimbursement provisions upon applicable restatements .
- Insider trading policy, including prohibitions on hedging/pledging and trading in derivatives/short selling/margin accounts, applies company-wide .
- Indemnification agreements cover executive officers (including General Counsel), providing defense and indemnity to fullest extent of Delaware law .
Compensation Structure Analysis
- Option Repricing: On December 16, 2023, the Board repriced certain previously granted and still outstanding unvested options under the 2021 and 2016 plans to $2.84 (closing price) without changing vesting or expirations; this affected directors and Named Executive Officers and is a governance-sensitive event indicative of compensation risk tolerance in down markets .
- EGC Status: As an emerging growth company, Rani provides scaled compensation disclosure and is not required to hold say‑on‑pay votes; this limits external feedback mechanisms on executive compensation practices .
- Bonus Discretion: Despite goal achievement in parts of 2023 and 2024, the Board awarded no cash bonuses to Named Executive Officers due to financial position; indicates cash conservation priority and discretionary override of performance pay .
Investment Implications
- Alignment positives: Company-wide prohibitions on hedging/pledging and a Dodd-Frank-compliant clawback policy enhance alignment and accountability for executives including the General Counsel .
- Disclosure limitations: As Eric Groen is not a Named Executive Officer, detailed compensation, equity grant, and severance terms are not disclosed; this constrains pay-for-performance and insider selling pressure analysis specific to him .
- Governance watchpoints: The 2023 option repricing for NEOs/directors is a compensation red flag to monitor in future grants; it signals willingness to modify equity terms in adverse markets (potentially dilutive or misaligned if repeated) .
- Policy frameworks reduce risk: Indemnification and insider trading controls provide standard protections and behavioral constraints; no pledging/hedging reduces alignment risk typically associated with insider financing or hedging strategies .